A resident of Governador Valadares, Thamires Fernandes, made headlines as the first woman in Minas Gerais and the third in Brazil to receive polylaminin, a yet-to-be-approved experimental treatment intended for spinal cord injury patients. This treatment involves a lab-created network of proteins derived from laminin, which is naturally produced by the body, particularly during fetal development. At 35, Thamires, who became paraplegic following an accident in December, was granted access to this treatment after pursuing a legal case just weeks after her injury.

Despite the promising nature of polylaminin, it is important to note that it has not undergone clinical trials approved by ANVISA, Brazil’s health regulatory agency, and is not available for public use. The lack of formal clinical studies has left the treatment in a purely investigational phase, yet it has ignited hope among patients with paraplegia and tetraplegia in Brazil and beyond. The excitement around polylaminin is evident, as it symbolizes a potential breakthrough in nerve regeneration, capturing attention from researchers and the medical community around the world.

Thamires expressed her feelings towards the treatment, describing it as 'a sign of hope.' This statement resonates with many individuals facing similar challenges, highlighting the emotional and psychological significance of emerging treatments in the realm of spinal cord injuries. As research in neuroregeneration continues to develop, the stories of patients like Thamires underscore the critical intersection of medical advancement and personal resilience often found in the journey of recovery.